SELLAS Life Sciences (SLS) Prepaid Assets (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Prepaid Assets of $4.0 million for Q1 2026, up 14.27% year-over-year from $3.5 million in Q1 2025, and up 19.71% quarter-over-quarter from $3.3 million in Q4 2025.
SELLAS Life Sciences (SLS) Prepaid Assets (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Prepaid Assets for 17 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 14.27% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 14.27% YoY), while the FY2025 annual figure was $3.3 million, up 41.73% from the prior year.
- Prepaid Assets improved to $4.0 million in Q1 2026 per SLS's latest filing, from $3.3 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $4.6 million in Q3 2025 and bottomed at $531000.0 in Q4 2022.
- Historically, Prepaid Assets has averaged $2.5 million across 5 years, with a median of $2.5 million in 2022.
- Annual changes were most pronounced in 2022 — Prepaid Assets slumped 66.58% — and 2024, when it jumped 331.92%.
- SELLAS Life Sciences' Prepaid Assets stood at $531000.0 in 2022, then gained by 2.07% to $542000.0 in 2023, then surged by 331.92% to $2.3 million in 2024, then soared by 41.73% to $3.3 million in 2025, then advanced by 19.71% to $4.0 million in 2026.
- Business Quant data shows SLS's Prepaid Assets at $4.0 million in Q1 2026, $3.3 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.06 Mn |
| Mar 31, 2026 | 3.97 Mn |
| Dec 31, 2025 | 3.32 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | 4.05 Mn |
| Mar 31, 2025 | 3.48 Mn |
| Dec 31, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 3.06 Mn |
| Mar 31, 2024 | 2.99 Mn |
| Dec 31, 2023 | 542,000.00 |
| Sep 30, 2023 | 1.13 Mn |
| Jun 30, 2023 | 1.67 Mn |
| Mar 31, 2023 | 2.02 Mn |
| Dec 31, 2022 | 531,000.00 |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 1.65 Mn |
| Mar 31, 2022 | 2.49 Mn |
| Dec 31, 2021 | 1.59 Mn |
| Sep 30, 2021 | 2.59 Mn |